A Phase 1b Study Evaluating the Safety, Tolerability and Immunogenicity of CMB305 (Sequentially Administered LV305 and G305) in Patients With Locally Advanced, Relapsed, or Metastatic Cancer Expressing NY-ESO-1

Trial Profile

A Phase 1b Study Evaluating the Safety, Tolerability and Immunogenicity of CMB305 (Sequentially Administered LV305 and G305) in Patients With Locally Advanced, Relapsed, or Metastatic Cancer Expressing NY-ESO-1

Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 12 Mar 2018

At a glance

  • Drugs CMB 305 (Primary)
  • Indications Non-small cell lung cancer; Ovarian cancer; Sarcoma; Solid tumours
  • Focus Adverse reactions; First in man
  • Sponsors Immune Design
  • Most Recent Events

    • 12 Mar 2018 Results published in the Immune Design media release.
    • 12 Mar 2018 According to an Immune Design media release, data from 25 NY-ESO-1+ soft tissue (STS) patients, including 14 synovial sarcoma patients was presented at the American Society of Clinical Oncology 2017 Annual Meeting.
    • 07 Nov 2017 According to the Immune design media release, data from this trial will be presented at the Society for Immunotherapy of Cancer (SITC) Annual Meeting in Nov 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top